

Appendix: Patient Group Conflict of Interest Declaration

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it.

Adam Waiser, an independent consultant, created the patient surveys, analyzed the data and wrote the initial draft submission with the assistance and oversight of Bladder Cancer Canada staff.

2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it.

Adam Waiser, an independent consultant, created the patient surveys, analyzed the data and wrote the first draft of the submission with the assistance and oversight of Bladder Cancer Canada staff.

3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

Below represents total over two years - 2017 and 2018

Company
Astra Zeneca
Bristol Myers Squibb
Janssen
Merck
Roche
Pfizer

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Signature:



Name: Tammy Northam
Position: Executive Director
Patient Group: Bladder Cancer Canada
Date: March 4, 2019